Exam (elaborations)
PHAR100 Final Exam Questions and Answers (Graded A)
PHAR100 Final Exam Questions and Answers
[Show more]
Preview 2 out of 14 pages
Uploaded on
November 15, 2024
Number of pages
14
Written in
2024/2025
Type
Exam (elaborations)
Contains
Questions & answers
Institution
PHAR 100
Course
PHAR 100
$11.99
100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached
PHAR100 Final Exam Questions and
Answers
How iiwas iihistorical iiuse iiof iisulfa iichemicals iicontributed iito iithe iiadvancement iiof
iipharmacology?
a) iiWeaponized iipoisons iiat iihigher iidoses iiwere iifound iito iihave iitherapeutic iieffects
b) iiUse iiof iisulfa iidrugs iilead iito iidevelopment iiof iifirst iisynthetic iiantibacterial
iicompounds
c) iiHistorical iiuse iiof iinatural iicompounds iiat iiultra iilow iidoses iiresulted iiin iitherapeutic
iieffects
d) iiExtraction iiof iichemical iicompounds iifrom iiman-made iipoisons iithat iiresulted iiin
iilarge-scale iihuman iiepidemics iiled iito iithe iidiscovery iiof iidrugs iistill iiused iitoday ii-
iiAnswers ii-b) iiUse iiof iisulfa iidrugs iilead iito iidevelopment iiof iifirst iisynthetic iiantibacterial
iicompounds
Which iihistorical iidrug iilisted iiis iistill iicommonly iiused iitherapeutically iitoday?
a) iiMa iiHuang
b) iiLSD
c) iiMorphine
d) iiCurare ii- iiAnswers ii-c) iiMorphine
Phase ii3 iiclinical iitrials iican iiemploy iia iiplacebo. iiWhich iione iiof iithe iistatment iimost
iiaccurately iidescribes iia iiplacebo?
a) iiA iiplacebo iiis iidefined iias iian iiinert iisubstacne iimasquerading iias iia iidrug
b) iiPlacebo iitherapy iiprovides iisatisfactory iirelief iiin iiapproximately ii55% iiof iisick
iianxious iipatients
c) iiLikelihood iiof iiplacebo iieffects iiis iigreater iiin iinormal iivolunteers iithan iiin iisick
iianxious iipatients iiunder iistress
d) iiPlacebo iiresponses iiare iiwell iiunderstood iiand iithus iineed iinot iibe iicontrolled iiin iia
iiphase ii3 iistudy ii- iiAnswers ii-a) iiA iiplacebo iiis iidefined iias iian iiinert iisubstacne
iimasquerading iias iia iidrug
The iisound iiand iilong iiestablished iiway iito iiprove iior iidisprove iithe iivalue iiof iia iinew
iimedication iior iitreatment iiis iia iirandomized iicontrolled iitrial ii(RCT). iiThis iimeans iithat:
a) iiPatients iiare iiselected iiand iiassigned iito iivarious iitest iigroups iibased iion iitheir
iicharacteristics
b) iiAll iipatients iireceive iithe iinew iidrug iior iithe iicontrol iidrug ii(gold-standard iior iiplacebo)
iion iialternating iidays
c) iiThe iipeople iiwho iiadminister iithe iidrugs iidon't iiknow iiwho's iireceiving iithe iidrug
d) iiOutcomes iimeasured iishould iipreferably iibe iisubjective ii- iiAnswers ii-c) iiThe iipeople
iiwho iiadminister iithe iidrugs iidon't iiknow iiwho's iireceiving iithe iidrug
, Drug iiA iionly iirelieves iipain iiof iimild iiintensity. iiDrug iiB iirelieves iipain iiof iivery iimarked
iiintensity. iiFrom iithis iiinformation, iione iiconcludes iithat:
a) iiDrug iiA iihas iigreater iiefficacy iithan iiDrug iiB
b) iiDrug iiB iihas iigreater iiefficacy iithan iiDrug iiA
c) iiDrug iiA iiis iimore iipotent iithan iiDrug iiB
d) iiDrug iiB iiis iimore iipotent iithan iiDrug iiA ii- iiAnswers ii-b) iiDrug iiB iihas iigreater iiefficacy
iithan iiDrug iiA
The iitherapeutic iirange iiis iibest iidescribed iias?
a) iiMaximum iipharmacological iiresponse iiproduced iiby iia iispecific iidrug iiin iithat
iibiological iisystem
b) iiThe iidose iior iiconcentration iiof iia iidrug iirequired iito iiproduce iia iiresponse iiof iia
iicertain iimagnitude iiusually ii50% iiof iithe iimaximal iiresponse iifor iithat iidrug
c) iiThe iidose iithat iiis iiappropriate iito iitreat iimost iiindividuals ii
d) iiThe iirange iiof iiblood iiceoncentration iiwhere iithe iidrug iiis iieffective iibut iitoxicities
iiusually iidon't iioccur ii- iiAnswers ii-d) iiThe iirange iiof iiblood iiceoncentration iiwhere iithe
iidrug iiis iieffective iibut iitoxicities iiusually iidon't iioccur
Ultra-short iiaction iiof iithiopental iiis iidue iito:
a) iiRedistribution iiof iithe iidrug iifrom iithe iibrain iito iimuscle iiand iifat
b) iiRapid iibreakdown iiin iiliver
c) iiPoor iipenetration iiinto iibrain
d) iiRapid iiexcretrion iiby iikidney ii- iiAnswers ii-a) iiRedistribution iiof iithe iidrug iifrom iithe
iibrain iito iimuscle iiand iifat
A iidrug iican iibe iigiven iito iia iipatient iiintravenously iiAND iiorally. iiWhat iishould iibe
iiconsidered iiwhen iiselecting iihte iimost iiappropriate iidosage iifor iithe iipatient's iisituation?
a) iiPharmacokinetics iiwould iibe iithe iiexact iisame iibecause iiit's iithe iisame iidrug
b) iiThe iisame iidose iiof iithe iidrug iineeds iito iibe iiprovided iibut iiIV iiadministration iiis
iipreferable iibecause iiit's iimore iireliable
c) iiDifferences iiin iibioavailability iineed iito iibe iicarefully iiconsidered
d) iiMore iiIV iidrugs iineed iito iibe iigiven iias iionset iiof iiaction iiis iislower ii- iiAnswers ii-c)
iiDifferences iiin iibioavailability iineed iito iibe iicarefully iiconsidered
Penicillin iihas iithe iiability iito iicombine iiwith iiproteins iito iiform iiantigens, iiand iia iismall
iipercentage iiof iithe iipopulation iireceiving iipenicillin iiexperience iiadverse iieffects. iiThis
iiadverse iieffect iiis iiproperly iiclassified iias:
a) iiExtension iiof iitherapeutic iieffect
b) iiTeratogenesis
c) iiDrug iiallergy
d) iiDrug iiaddiction ii- iiAnswers ii-c) iiDrug iiallergy
The iiTD50 iiof iia iidrug iiin iirats iiis ii50mg/kg. iiThe iiED50 iiof iithe iisame iidrug iiin iirats iiis
ii1mg/kg. iiFrom iithis iiinformation, iithe iitherapeutic iiindex iiof iithe iidrug iiin iirats iiis...
a) ii0.02